Kumar Rajesh, Ledet Grace, Graves Richard, Datta Dibyadyuti, Robinson Shana, Bansal Geetha P, Mandal Tarun, Kumar Nirbhay
Department of Tropical Medicine and Vector-Borne Infectious Diseases Research Center, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, 70112, USA.
Center for Nanomedicine & Drug Delivery, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Pharm Res. 2015 Dec;32(12):3827-36. doi: 10.1007/s11095-015-1743-x. Epub 2015 Jun 26.
To evaluate functional immunogenicity of CHrPfs25. a malaria transmission blocking vaccine antigen, using nanoemulsion and porous polymeric PLGA nanoparticles.
CHrPfs25 was formulated with nanoemulsions (NE) and poly(D,L-lactide-co-glycolide) nanoparticles (PLGA-NP) and evaluated via IM route in mice. Transmission blocking efficacy of antibodies was evaluated by standard mosquito membrane feeding assay using purified IgG from immune sera. Physicochemical properties and stability of various formulations were evaluated by measuring poly-dispersity index, particle size and zeta potential.
Mice immunized with CHrPfs25 using alum via IP and IM routes induced comparable immune responses. The highest antibody response was obtained with CHrPfs25 formulated in 4% NE as compared to 8% NE and PLGA-NP. No further increases were observed by combining NE with MPL-A and chitosan. One hundred percent transmission blocking activity was demonstrated at 400 μg/ml of IgG for alum groups (both routes IP and IM), 4% NE and NE-MPL-A. Purified IgG from various adjuvant groups at lower doses (100 μg/mL) still exhibited >90% transmission blocking activity, while 52-81% blocking was seen at 50 μg/mL.
Results suggest that CHrPfs25 delivered in various adjuvants/nanoparticles elicited strong functional immunogenicity in pre-clinical studies in mice. We are now continuing these studies to develop effective vaccine formulations for further evaluation of immune correlates of relative immunogenicity of CHrPfs25 in various adjuvants and clinical trials.
使用纳米乳剂和多孔聚合物聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒评估疟疾传播阻断疫苗抗原CHrPfs25的功能免疫原性。
将CHrPfs25与纳米乳剂(NE)和聚(D,L-丙交酯-共-乙交酯)纳米颗粒(PLGA-NP)配制在一起,并通过肌内途径在小鼠中进行评估。使用来自免疫血清的纯化IgG,通过标准蚊媒膜饲育试验评估抗体的传播阻断效力。通过测量多分散指数、粒径和zeta电位来评估各种制剂的物理化学性质和稳定性。
通过腹腔注射(IP)和肌内注射(IM)途径用明矾免疫的小鼠诱导了相当的免疫反应。与8%的NE和PLGA-NP相比,用4%的NE配制的CHrPfs25获得了最高的抗体反应。将NE与MPL-A和壳聚糖联合使用未观察到进一步的增加。对于明矾组(IP和IM途径)、4%的NE和NE-MPL-A,在400μg/ml的IgG时显示出100%的传播阻断活性。来自各种佐剂组的较低剂量(100μg/mL)的纯化IgG仍表现出>90%的传播阻断活性,而在50μg/mL时观察到52-81%的阻断。
结果表明,在小鼠的临床前研究中,以各种佐剂/纳米颗粒递送的CHrPfs25引发了强大的功能免疫原性。我们现在正在继续这些研究,以开发有效的疫苗制剂,用于进一步评估CHrPfs25在各种佐剂中的相对免疫原性的免疫相关性以及进行临床试验。